SCHEMBL209580

SCHEMBL209580

CC(C)C(=O)N(C)c1cc(Cl)ccn1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FGFR4 P22455 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
FFAR2 O15552 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CNR2 P34972 1/20 0.36
FSCN1 Q16658 1/20 0.36
IDH1 O75874 1/20 0.35
MLYCD O95822 1/20 0.35
NUDT1 P36639 1/20 0.34
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28393110 0.78 HRH4 (0.40) KDM4CMLYCD
SCHEMBL7914638 0.75 PTK2 (0.40) ALDH1A1MAPTL3MBTL1KMT2AFFAR2
SCHEMBL210401 0.75 MLYCD (0.34) ALDH1A1SMN1; SMN2MLYCD
SCHEMBL26763994 0.75 LIPE (0.50) ALDH1A1POLBKMT2ALMNA
SCHEMBL29650144 0.74 CNR2 (0.42) KDM4CALDH1A1MAPTL3MBTL1FGFR4
SCHEMBL3928632 0.74 CNR2 (0.42) KDM4CALDH1A1MAPTL3MBTL1FGFR4
SCHEMBL827405 0.73 ALDH1A1 (0.41) ALDH1A1MAPTL3MBTL1KMT2A
Hydrochloric Acid SCHEMBL5743227 0.71 ALDH1A1 (0.40) ALDH1A1MAPTL3MBTL1KMT2A
SCHEMBL6024222 0.71 CHRNB2 (0.40) ALDH1A1MAPTL3MBTL1FGFR4KMT2A
SCHEMBL1219392 0.69 FGFR4 (0.39) KDM4CALDH1A1MAPTL3MBTL1FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150299185-A1 NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR HANMI PHARM. CO., LTD. (KR) 2015-10-22 US disclosed
EP-2797909-A1 NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR Hanmi Pharm. Co., Ltd. (KR) 2014-11-05 EP disclosed
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
WO-2013100631-A1 NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR HANMI PHARM. CO., LTD. (KR) 2013-07-04 WO disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
EP-1963315-A2 ENZYME INHIBITORS The Institute of Cancer Research (GB) 2008-09-03 EP disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 WO disclosed
US-6214801-B1 INHIBITION OF DNA OR RNA VIRAL PROLIFERATION THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2001-04-10 US disclosed
WO-1997027205-A1 IMIDAZO[1,2-A]PYRIDINE C-NUCLEOSIDES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299185-A1 NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR LCK, ABL1, TYK2 KDM4C 1223/4885ALDH1A1 3703/4885MAPT 2021/4885
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA KDM4C 442/4885ALDH1A1 3015/4885MAPT 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.